Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 222 participants.

Also called NCT02949193

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 222 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02949193
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02949193. Randomized; quadruple masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2014-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
evogliptin
Intervention (Drug)
Sitagliptin
Lead sponsor
Dong-A ST Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02949193
Content hash
cc658bef6a6659155bba919bc1c95ab2323b92f45dea41eca6f7b664bfe8f83e